Table 3 Clinical trials-thalidomide (Relapsed/refractory disease)
From: Thalidomide and its analogues in the treatment of Multiple Myeloma
Author | Regimen | Type of clinical trial | No. of pts | Best responses (>PR) | CR, nCR, VGPR | PFS/TTP/OS (months) | Reference |
|---|---|---|---|---|---|---|---|
Barlogie et al | T | Phase II | 169 | 30% | CR:2% | 2 yr EPS:20% 2 yr OS;48% | Blood 2001 |
Palumbo et al | TD | Phase II | 62(FR), 58(SR) | 56% (FR), 46% (SR) | Not reported | PPS:17(FR),11(SR) OS:60%(FR,3-yr),19(SR) | Hematol J 2004 |
Dimpopoulus et al | TD | Phase II | 44 | 55% | >VGPR:30% | Median survival 12.6 | Annal Oncol 2001 |
Moehler et al | DT-PACE | Phase II | 50 | 65% | CR:4% | PPS:15 1 yr OS:63% | Bllod 2001 |
Terpos E et al | VMDT | Phase II | 62 | 66% | CR:13% VGPR:27% | TTP: 9.7 | Leukemia 2008 |
Palumbo et al | VMDT | Phase II | 30% | 67% | VGPR:43% | PPS (1 yr):61% OS (1 yr):84% | Blood 2007 |